Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 15, 2017 (9 years ago)

Succinylcholine Chloride Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Sterility Assurance

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Succinylcholine Chloride Injection, USP 200 mg (20 mg/mL) Quelicin Multiple-dose vial, 10 mL, For I.V. or I.M. use. a.) one vial (NDC: 0409-6629-02), b.) 25 vial carton (NDC: 0409-6629-25).

Affected NDCs 0409-6629-02 0409-6629-25

Compare with the code on your package — it is the most precise check available.

Drug: Succinylcholine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Quelicin
Succinylcholine Chloride
NDC 00409-6629
20 mg/mL Injection, Solution
Intramuscular|intravenous
Hospira, Inc. Rx
Recalling firm
Hospira a Pfizer Company
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1048-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Succinylcholine recalls

See all
Class II · Moderate risk

Succinylcholine Chloride Injection

Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 70710-1377-1 D-0623-2025

Other recalls by Hospira a Pfizer Company

All 2017 recalls
Class II · Moderate risk

Labetalol Hydrochloride Injection

Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.

Terminated Packaging defect Hospira Inc. A Pfizer Company NDC 0409-2267-20 D-0576-2018
Class III · Low risk

Argatroban Injection

Failed Impurities/Degradation Specifications; out of specification result for denitroquinoline-related impurity during three month time point

Terminated Impurity / degradation Hospira Inc., A Pfizer Company NDC 0409-1140-01 D-0980-2017